KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Non-Current Deferred Tax Liability (2016 - 2023)

Inovio Pharmaceuticals' Non-Current Deferred Tax Liability history spans 14 years, with the latest figure at $2.0 million for Q4 2023.

  • For Q4 2023, Non-Current Deferred Tax Liability rose 6119.18% year-over-year to $2.0 million; the TTM value through Dec 2023 reached $2.0 million, up 6119.18%, while the annual FY2023 figure was $2.0 million, 6119.18% up from the prior year.
  • Non-Current Deferred Tax Liability for Q4 2023 was $2.0 million at Inovio Pharmaceuticals, up from $32046.0 in the prior quarter.
  • Across five years, Non-Current Deferred Tax Liability topped out at $2.0 million in Q4 2023 and bottomed at $24766.0 in Q1 2019.
  • The 5-year median for Non-Current Deferred Tax Liability is $32046.0 (2019), against an average of $129190.0.
  • The largest annual shift saw Non-Current Deferred Tax Liability changed 0.0% in 2019 before it soared 6119.18% in 2023.
  • A 5-year view of Non-Current Deferred Tax Liability shows it stood at $32046.0 in 2019, then changed by 0.0% to $32046.0 in 2020, then changed by 0.0% to $32046.0 in 2021, then changed by 0.0% to $32046.0 in 2022, then skyrocketed by 6119.18% to $2.0 million in 2023.
  • Per Business Quant, the three most recent readings for INO's Non-Current Deferred Tax Liability are $2.0 million (Q4 2023), $32046.0 (Q3 2023), and $32046.0 (Q2 2023).